• Robert C Bast, J Tate Thigpen, Susan G Arbuck, Karen Basen-Engquist, Laurie B Burke, Ralph Freedman, Sandra J Horning, Robert Ozols, Gordon J Rustin, David Spriggs, Lari B Wenzel, and Richard Pazdur.
• M. D. Anderson Cancer Center, Houston, TX, USA.
• Gynecol. Oncol. 2007 Nov 1; 107 (2): 173-6.

ObjectiveThe unique characteristics of cancer, particularly issues involving the use of surrogate endpoints in clinical trials, present special challenges in the development of cancer drugs. In response, the U.S. Food and Drug Administration (FDA) has partnered with the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Hematology to conduct public workshops evaluating potential endpoints for drug approvals for the most common tumor types.MethodsA workshop evaluating potential endpoints in ovarian cancer drug research was held in Bethesda, Maryland, in April 2006. Invited experts presented research findings and discussed endpoints in trials of drugs for treatment of Stage III and IV ovarian cancer.ResultsThe panel responded to specific questions from FDA, discussing use of progression-free survival as a surrogate for overall survival and use of CA-125 levels as an indicator of response. Panel members also addressed endpoints in first-line therapy, second-line and subsequent therapy, and maintenance therapy.ConclusionExpert commentary provided by panel members will inform FDA's draft guidance on clinical endpoints for cancer drug approvals and will be discussed at meetings of the FDA's Oncologic Drugs Advisory Committee. FDA intends to develop a set of principles that can be used to define efficacy standards for drugs used to treat ovarian and other cancers.

25 keywords...

hide…